Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Short Interest Update

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 134,600 shares, a growth of 102.7% from the December 15th total of 66,400 shares. Currently, 2.2% of the shares of the stock are short sold. Based on an average trading volume of 3,450,000 shares, the days-to-cover ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

CYCC has been the topic of a number of recent analyst reports. Roth Capital cut shares of Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals in a research report on Friday, January 10th. They set a “sell” rating for the company.

Institutional Investors Weigh In On Cyclacel Pharmaceuticals

An institutional investor recently bought a new position in Cyclacel Pharmaceuticals stock. Armistice Capital LLC bought a new stake in shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned approximately 9.18% of Cyclacel Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 23.58% of the company’s stock.

Cyclacel Pharmaceuticals Trading Down 3.5 %

Shares of CYCC stock traded down $0.01 during trading hours on Thursday, hitting $0.35. The company’s stock had a trading volume of 281,838 shares, compared to its average volume of 12,324,971. The business has a fifty day moving average of $0.38 and a 200-day moving average of $0.91. Cyclacel Pharmaceuticals has a twelve month low of $0.31 and a twelve month high of $4.00. The stock has a market cap of $2.22 million, a price-to-earnings ratio of -0.04 and a beta of 0.35.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.36. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.